The content of this presentation is provided to an audience of international healthcare professionals for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.
Scientific publications at ASN Kidney Week 2023.
Thank you for your interest! Please see below to download the posters/presentations at ASN 2023. Presentations, Videos and Posters will be available following the presentation at the congress.
Some of the links to view the Presentations or Posters will link to the official ASN 2023 web page. You may need to be a registered delegate and logged in the respective platform to view the content.
Finerenone
November 4, 2023 from 10:00 AM to 12:00 PM
End-stage kidney disease-free survival time in patients with CKD and T2D in FIDELITY
Session: Diabetic Kidney Disease: Clinical - II [PO0702-2] Lead author: Ajay Singh
November 3, 2023 from 10:00 AM to 12:00 PM
Design and Baseline Characteristics of the FIND-CKD Trial: Efficacy of Finerenone on Kidney Disease Progression in People with Non-Diabetic Chronic Kidney Disease (CKD)
Session: CKD Interventions: Trials and Quality Improvement [PO2302-2] Lead author: Hiddo Heerspink
November 3, 2023 from 10:00 AM to 12:00 PM
Rationale and design of a Phase 3 registration trial investigating finerenone in participants with chronic kidney disease and type 1 diabetes using a UACR endpoint (FINE-ONE)
Lead author: Hiddo Heerspink
November 4, 2023 from 10:00 AM to 12:00 PM
Interim Results From FINE-REAL: A Prospective Study Providing Insights Into the Use of Finerenone in Routine Clinical Settings
Session: Diabetic Kidney Disease: Clinical - II [PO0702-2] Lead author: Susanne B. Nicholas
November 4, 2023 from 10:00 AM to 12:00 PM
Early use and effectiveness of finerenone in US patients with chronic kidney disease and type 2 diabetes - a FOUNTAIN platform analysis
Session: Diabetic Kidney Disease: Clinical - II [PO0702-2]Lead author: Nikolaus Oberprieler